Rafael Holdings Files 8-K Report
Ticker: RFL · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1713863
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Rafael Holdings filed an 8-K, likely with important updates.
AI Summary
On December 23, 2024, Rafael Holdings, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No specific details regarding transactions, agreements, or financial figures were disclosed in the provided excerpt.
Why It Matters
This filing signals that Rafael Holdings, Inc. is making a regulatory disclosure to the SEC, which could pertain to significant corporate events.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific disclosed risks or material events.
Key Players & Entities
- Rafael Holdings, Inc. (company) — Registrant
- December 23, 2024 (date) — Date of earliest event reported
- 520 Broad Street Newark, New Jersey 07102 (address) — Principal executive offices
FAQ
What is the specific nature of the "Other Events" reported by Rafael Holdings, Inc. on December 23, 2024?
The provided excerpt does not specify the nature of the "Other Events"; it only indicates that this item is being reported under the 8-K form.
What is Rafael Holdings, Inc.'s standard industrial classification?
Rafael Holdings, Inc.'s standard industrial classification is "PHARMACEUTICAL PREPARATIONS [2834]."
What is the fiscal year end for Rafael Holdings, Inc.?
The fiscal year end for Rafael Holdings, Inc. is July 31.
What is the SEC file number for Rafael Holdings, Inc.?
The SEC file number for Rafael Holdings, Inc. is 001-38411.
What is the business phone number listed for Rafael Holdings, Inc.?
The business phone number listed for Rafael Holdings, Inc. is 212-658-1450.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-23 16:55:58
Key Financial Figures
- $0.01 — tered Class B common stock, par value $0.01 per share RFL New York Stock Exchan
- $3,000,000 — 24, in the original principal amount of $3,000,000, converted $2,500,000 of the outstandin
- $2,500,000 — incipal amount of $3,000,000, converted $2,500,000 of the outstanding balance of the Note
- $0 — n"). The conversion price was equal to $0.63, which was the closing price of Cycl
Filing Documents
- ea0225818-8k_rafael.htm (8-K) — 23KB
- 0001213900-24-111976.txt ( ) — 190KB
- rfl-20241223.xsd (EX-101.SCH) — 3KB
- rfl-20241223_lab.xml (EX-101.LAB) — 33KB
- rfl-20241223_pre.xml (EX-101.PRE) — 22KB
- ea0225818-8k_rafael_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 23, 2024, Rafael Holdings, Inc. (the "Company"), in accordance with the terms of the Convertible Promissory Note (the "Note") made by Cyclo Therapeutics, Inc. ("Cyclo") in favor of the Company, with an issue date of August 21, 2024, in the original principal amount of $3,000,000, converted $2,500,000 of the outstanding balance of the Note into 3,968,254 shares of common stock of Cyclo (the "Conversion"). The conversion price was equal to $0.63, which was the closing price of Cyclo's common stock on The Nasdaq Capital Market on December 20, 2024, the trading date immediately preceding the date of the Conversion. Following the Conversion the Company beneficially owns 39.5% of the issued and outstanding shares of Cyclo's common stock. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAFAEL HOLDINGS, INC. By: /s/ William Conkling Name: William Conkling Title: Chief Executive Officer Dated: December 23, 2024 2